BioSpace News Archive

Verastem, Inc., a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, announced the grant of options to purchase 20,000 shares of its common stock to two new employees.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that data presented at the 23 rd International AIDS Conference virtual meeting, demonstrates that ibalizumab is active in vitro against group A and group B HIV-2. Ibalizumab in vitro activity against HIV-2 The objective of the study, conducted by a team of researchers at Bichat-Claude Bernard Hospital and Sa

The CEO of BetterLife Pharma (OTCQB:BETRD) (CSE: BETR) (FRANKFURT: NPAT), an emerging clinical stage pharmaceutical development company, recently discussed the use of interferon therapy for COVID-19 with Alex Keown of BioSpace . Highlights of the interview include: BetterLife CEO Dr. Ahmad Doroudian noting that the coronavirus creates a number of problems in the body, but chief among them is the virus’s ability to suppress interferon produ

On July 1, 2020, a fraudulent “short report” was posted. The fraudulent report includes manipulated company graphs and figures, fraudulent misrepresentation of data, and factual misstatements. Applied Therapeutics will work with law enforcement and regulators to ensure this criminal stock manipulation is prosecuted to the fullest extent of the law. NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developin

Mesoblast Limited announced that an expanded access protocol has been initiated in the United States for compassionate use of its allogeneic mesenchymal stem cell product candidate remestemcel-L in the treatment of COVID-19 infected children with cardiovascular and other complications of multisystem inflammatory syndrome.

Mylan N.V. announced that the Drug Controller General of India has approved its remdesivir 100 mg/vial for restricted emergency use in India as part of the DCGI’s accelerated approval process to address urgent, unmet needs amid the evolving coronavirus 2019 pandemic.

89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, announced that it has commenced an underwritten public offering of 2,200,000 shares of its common stock.

Simple new assay leverages more than 25,000 BD Veritor™ instruments already used across the U.S. to immediately increase access to COVID-19 testing in frontline health care settings

NuVera Medical Inc., a portfolio company of Shifamed LLC, focused on enabling a new era in transcatheter cardiac interventions through the advancement of real-time 3D intracardiac echocardiography, announced initiation of the company’s first-in-human clinical trial to evaluate the performance of its novel NuVision™ ICE Catheter.

Akero Therapeutics, Inc., a cardio-metabolic non-alcoholic steatohepatitis company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, announced that it has commenced an underwritten public offering of 4,750,000 shares of its common stock.